Tag Archives: NASDAQ:CDTX

A Director at Cidara Therapeutics (NASDAQ: CDTX) is Buying Shares

Yesterday, a Director at Cidara Therapeutics (CDTX – Research Report), Timothy Franson, bought shares of CDTX for $14.77K. This recent transaction increases Timothy Franson’s holding in the company by 175% to a total of $23.21K. In addition to Timothy Franson,

Maxim Group Gives a Buy Rating to Cidara Therapeutics (CDTX)

Maxim Group analyst Jason McCarthy assigned a Buy rating to Cidara Therapeutics (CDTX – Research Report) yesterday and set a price target of $10.00. The company’s shares closed last Friday at $2.32. According to TipRanks.com, McCarthy is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: and Cidara Therapeutics (NASDAQ: CDTX)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Cidara Therapeutics (CDTX – Research Report) with bullish sentiments. TipRanks has tracked 36,000 company insiders and found that a few of

Maxim Group Maintains a Buy Rating on Cidara Therapeutics (CDTX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) yesterday and set a price target of $10.00. The company’s shares closed last Friday at $3.81. According to TipRanks.com, McCarthy is a 5-star analyst

Oppenheimer Maintains Their Buy Rating on Cidara Therapeutics (CDTX)

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $6.00. The company’s shares closed last Thursday at $3.78. According to TipRanks.com, DeGeeter is a

Cidara Therapeutics (CDTX) Received its Third Buy in a Row

After Needham and Wedbush gave Cidara Therapeutics (NASDAQ: CDTX) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Kevin DeGeeter maintained a Buy rating on Cidara Therapeutics today and set a price target of